Greenlight Biosciences Inc., of Boston, said it raised an oversubscribed $102 million round of funding from new and existing investors to expand production of its RNA products for agricultural and life sciences applications, including an expansion into new RNA-based therapies. The round was led by Morningside Ventures, with several new and existing top-tier investors participating. The investment follows on the heels of a $17 million special purpose round in May to accelerate large-scale manufacturing of future COVID-19 vaccines using the company's messenger RNA production technology. The new funding will drive the expansion of its human health efforts into new platforms such as RNA-based therapeutics.
Yumab GmbH, of Braunschweig, Germany, which said it previously identified fully human monoclonal antibodies with neutralizing activity against live coronavirus strain SARS-CoV-2 using its antibody discovery platform, disclosed the first financing round of its spin-off, Corat Therapeutics GmbH, to advance development of the COVID-19 antibody candidates. The specific amount was not disclosed, but financial investments were provided by the German Federal State of Lower Saxony and a group of private investors from Braunschweig. Corat will continue the preclinical development of the lead antibody candidate to potentially begin clinical development by the end of 2020.